| ID | 原文 | 译文 |
| 987 | 区间8～15d），持续病毒核酸检测阴性时间（持续2次以上病毒核酸检测阴性且两次 间隔24h）为13.5d（95%可信区间9.5～17.5d）。 | The duration of negative nucleic acid test result (negative for more than 2 times consecutively with interval ≥ 24h) was 13. 5 days (95% CI: 9.5 - 17.5 days). |
| 988 | 基础方案效果不佳，可以尝试使用磷酸氯喹（18岁-65岁成人。体重>50公斤者，每次500mg bid；体重<50公斤者，第一、二天每次500mg bid，第三至第七天每次500mg qd）。 | If the basic regimen is not effective, chloroquine phosphate can be used on adults between 18- 65 years old (weight ≥ 50 kg: 500 mg bid; weight ≤ 50 kg: 500 mg bid for first two days, 500 mg qd for following five days). |
| 989 | 我国新冠病毒肺炎诊疗方案推荐使用干扰素雾化吸入治疗，我们建议在负压病房进行。因雾化易诱发气溶胶播散，不建议普通病房内开展雾化吸入治疗。 | Interferon nebulization is recommended in Protocols for Diagnosis and Treatment of COVID-19. We recommend that it should be performed in negative-pressure wards rather than general wards due to the possibility of aerosol transmission. |
| 990 | 根据艾滋病患者用药经验，达芦那韦/考比司他的不良反应相对较轻，体外病毒抑制试验具有一定程度抗病毒活性，对不耐受洛匹那韦/利 | Darunavir/cobicistat has some degree of antiviral activity in viral suppression test in vitro, based on the treatment experience of AIDS patients, and the adverse events are relatively mild. |
| 991 | 托那韦的患者，在通过伦理审查后可考虑口服达芦那韦/考比司他（1片 qd）或者法匹那韦（首剂1600mg，后续600mg tid）代替。 | For patients who are intolerant to lopinavir/ritonavir, darunavir/cobicistat (1 tablet qd) or favipiravir (star ting dose of 1600 mg followed by 600 mg tid) is an alternative option after the ethical review. |
| 992 | 不建议同时应用3种及以上抗病毒药物。 | Simultaneous use of three or more antiviral drugs is not recommended. |
| 993 | 疗程 | Course of Treatment |
| 994 | 磷酸氯喹疗程≤7天；其他方案的疗程尚未确定，一般为2周，或痰液病毒核酸检测结果持续3次以上阴性可考虑停用抗病毒药物。 | The treatment course of chloroquine phosphate should be no more than 7 days. The treatment course of other regimens has not been determined and are usually around 2 weeks. Antiviral drugs should be stopped if nucleic acid test results from sputum specimens remain negative for more than 3 times. |
| 995 | 七. 抗休克及抗低氧血症维持生命体征 | VII. Anti-shock and Anti-hypoxemia Treatment |
| 996 | COVID-19从重型向危重型发展时，患者可出现严重低氧血症、细胞因子风暴、继发重型感染，进而发生休克，出现组织灌注障碍，甚至多器官功能衰竭，治疗上以纠正诱发因素和液体复苏为主。 | During the progression from the severe to critically ill stage, patients may develop severe hypoxemia, cytokine cascade and severe infections that might develop into shock, tissue per fusion disorders, and even multiple organ failure. Treatment is aimed at incentive removal and fluid recovery. |